Search Results for "fenofibric acid"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for fenofibric acid. Results 1 to 6 of 6 total matches.
See also: Trilipix
Lipid-Lowering Drugs
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022 (Issue 1659)
once/day or divided26 421.2023
5 g/scoop
Fibric Acid Derivatives
Fenofibrate – generic 54, 160 mg ...
Cholesterol management guidelines from the
American College of Cardiology/American Heart
Association Task Force were last published in 2019.
Comparison Table: Some Lipid-Lowering Drugs (online only)
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022 (Issue 1659)
48 mg once/day
Severe (including dialysis):
contraindicated
42.50
31.00
Fenofibric acid ...
View the Comparison Table: Some Lipid-Lowering Drugs
Elafibranor (Iqirvo) for Primary Biliary Cholangitis
The Medical Letter on Drugs and Therapeutics • Dec 23, 2024 (Issue 1718)
acid (UDCA)
and fenofibrate in primary biliary cholangitis patients with
incomplete UDCA response ...
Elafibranor (Iqirvo – Ipsen), a peroxisome proliferator-activated
receptor (PPAR) agonist, has been granted
accelerated approval by the FDA for treatment of
primary biliary cholangitis (PBC) in adults. It is
indicated for use in combination with ursodeoxycholic
acid (ursodiol, UDCA; Urso, and others) in patients
with an inadequate response to UDCA alone and as
monotherapy in those unable to tolerate UDCA.
Med Lett Drugs Ther. 2024 Dec 23;66(1718):202-4 doi:10.58347/tml.2024.1718b | Show Introduction Hide Introduction
Seladelpar (Livdelzi) for Primary Biliary Cholangitis
The Medical Letter on Drugs and Therapeutics • Jan 20, 2025 (Issue 1720)
.
3. AC Cheung et al. Combined ursodeoxycholic acid (UDCA) and
fenofibrate in primary biliary ...
Seladelpar (Livdelzi – Gilead), a peroxisome
proliferator-activated receptor (PPAR)-delta agonist,
has received accelerated approval from the FDA for use
in combination with ursodeoxycholic acid (ursodiol,
UDCA; Urso Forte, and generics) for treatment of
primary biliary cholangitis (PBC) in adults who had an
inadequate response to UDCA and as monotherapy in
those unable to tolerate UDCA. Accelerated approval
was based on a reduction in alkaline phosphatase
(ALP) levels. Seladelpar is the second PPAR agonist
to be approved in the US for this indication; elafibranor
(Iqirvo)...
Med Lett Drugs Ther. 2025 Jan 20;67(1720):13-5 doi:10.58347/tml.2025.1720d | Show Introduction Hide Introduction
Table: Inhibitors and Inducers of CYP Enzymes, P-Glycoprotein, and Other Transporters (online only)
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023 (Issue 1669)
)
amiodarone
capecitabine
ceritinib
delavirdine
efavirenz
etravirine
fenofibrate
floxuridine ...
View the Inhibitors and Inducers of CYP Enzymes, P-Glycoprotein, and Other Transporters tables
Med Lett Drugs Ther. 2023 Feb 6;65(1669):e28-30 doi:10.58347/tml.2023.1669g | Show Introduction Hide Introduction
Drugs for Gout
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023 (Issue 1688)
of combination treatment using antihyperuricaemic
agents with fenofibrate and/or losartan on uric
acid ...
Drugs for gout are used to reduce the pain and
inflammation of acute flares, decrease the frequency
of exacerbations, and lower serum urate levels to
prevent recurrent flares, development of tophi, and
joint damage.
Med Lett Drugs Ther. 2023 Oct 30;65(1688):169-75 doi:10.58347/tml.2023.1688a | Show Introduction Hide Introduction